TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35729900

Group type: EXPERIMENTAL
Intervention: Coping strategies such as talking with family and friends, participating in family activities, physical activity, sleeping well at night, eating healthier, and increasing personal care.
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Increased time with screens, eating fast food, substance use, and frequent communication with health professionals.
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Younger women, primiparous women, and those with more exposure to COVID-19.
Number of subjects: 3356

Group type: COMPARATOR
Intervention: General population of pregnant and postpartum women.
Number of subjects: 3356
Study: 35730131

Group type: EXPERIMENTAL
Intervention: PF-05251749 (0.3-100 μM)
Number of subjects: 0
Study: 35730213

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 1131
Study: 35730447

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 740
Study: 35730475

Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched asymptomatic volunteers)
Number of subjects: 16
Study: 35730586

Group type: EXPERIMENTAL
Intervention: Daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD)
Number of subjects: 87
Study: 35730761

Group type: EXPERIMENTAL
Intervention: Trail running races (40 to 171 km)
Number of subjects: 52
Study: 35731242

Group type: EXPERIMENTAL
Intervention: Active surveillance following an FDG-negative nodule
Number of subjects: 126

Group type: COMPARATOR
Intervention: Diagnostic surgery for benign histopathology
Number of subjects: 126

Group type: COMPARATOR
Intervention: Patients with malignant histopathology
Number of subjects: 126
Study: 35731340

Group type: COMPARATOR
Intervention: US representative sample of men (no prostate cancer)
Number of subjects: 876
Study: 35731373

Group type: EXPERIMENTAL
Intervention: Total cold-water immersion (TCWI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ice massage (IM)
Number of subjects: 60
Study: 35731464

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention targeting addictive overeating with a displacement mechanism component
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Core 'Dread List' feature of the mobile intervention
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dread items related to school
Number of subjects: 37
Study: 35731551

Group type: EXPERIMENTAL
Intervention: Uneven treadmill training (up to 12 sessions over 6 weeks)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard rehabilitation care
Number of subjects: 3
Study: 35731565

Group type: EXPERIMENTAL
Intervention: mHealth lifestyle intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 68
Study: 35731564

Group type: EXPERIMENTAL
Intervention: Gamification
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Neumorphism
Number of subjects: 434

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 434
Study: 35731566

Group type: EXPERIMENTAL
Intervention: Primary care management activities during patient encounters
Number of subjects: 176

Group type: COMPARATOR
Intervention: Comparison of morbidity and management patterns between private and public sectors
Number of subjects: 176
Study: 35731634

Group type: EXPERIMENTAL
Intervention: Community-based integrated HIV and sexual and reproductive health intervention (CHIEDZA) during the COVID-19 pandemic
Number of subjects: 0
Study: 35731948

Group type: EXPERIMENTAL
Intervention: Moxifloxacin AUC0-24/MIC target of 58
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Levofloxacin AUC0-24/MIC of 118.3
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Clofazimine AUC0-24/MIC of 50.5
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Pyrazinamide AUC0-24 of 379 mg × h/L
Number of subjects: 290
Study: 35731991

Group type: EXPERIMENTAL
Intervention: Procarbazine, Lomustine, and Vincristine chemotherapy
Number of subjects: 0
Study: 35732012

Group type: EXPERIMENTAL
Intervention: Open-set response format in speech-weighted noise
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Closed-set response format
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Phonetically similar words in speech-weighted noise
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 4 AFC picture-pointing paradigm
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Open-set response format in quiet
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Developmental change for word recognition
Number of subjects: 250
Study: 35732151

Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35732155

Group type: EXPERIMENTAL
Intervention: P. vivax serological markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panel of eight P. vivax proteins
Number of subjects: 0
Study: 35732222

Group type: EXPERIMENTAL
Intervention: SGLT2-I users
Number of subjects: 324

Group type: COMPARATOR
Intervention: Non-SGLT2-I users
Number of subjects: 324
Study: 35732441

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1088
Study: 35732870

Group type: EXPERIMENTAL
Intervention: Abbott Nucleoprotein assay (Abbott-N)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roche Elecsys Nucleoprotein assay (Roche-N)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSD Spike assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roche Elecsys Spike assay (Roche-S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roche Elecsys Spike assay
Number of subjects: 0
Study: 35733142

Group type: EXPERIMENTAL
Intervention: Harvest for Health mentored vegetable gardening intervention
Number of subjects: 100
Study: 35734087

Group type: EXPERIMENTAL
Intervention: Booster COVID-19 mRNA vaccination during pregnancy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Primary 2-dose series of COVID-19 mRNA vaccination during pregnancy
Number of subjects: 240
Study: 35735167

Group type: EXPERIMENTAL
Intervention: Friend-oriented networks with weekly contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-to-moderate networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals with many close confidants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals reporting moderately frequent contact with moderately-sized networks
Number of subjects: 0
Study: 35736814

Group type: EXPERIMENTAL
Intervention: Ultrahigh dose-rate radiation (FLASH); single dose; specific dosage not mentioned.
Number of subjects: 0
Study: 35736816

Group type: EXPERIMENTAL
Intervention: Neoadjuvant talazoparib for 8 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Neoadjuvant talazoparib
Number of subjects: 13
Study: 35737143

Group type: EXPERIMENTAL
Intervention: EuroQol-5D-5L (EQ-5D-5L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EORTC-QLQ-C30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HADS anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HADS depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRQoL questionnaires
Number of subjects: 0
Study: 35737291

Group type: EXPERIMENTAL
Intervention: Experimental EDOF contact lens
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single-vision control lens
Number of subjects: 72
Study: 35737298

Group type: EXPERIMENTAL
Intervention: ddBCMA CAR T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCMA-directed scFv-based C11D5.3 CAR
Number of subjects: 0
Study: 35737430

Group type: EXPERIMENTAL
Intervention: HoloLens mixed reality headset for needle guidance
Number of subjects: 7
Study: 35737443

Group type: EXPERIMENTAL
Intervention: Remotely delivered behavioral weight loss intervention using an ad libitum whole food plant-based diet (WFPBD) over 12 weeks
Number of subjects: 15
Study: 35737454

Group type: EXPERIMENTAL
Intervention: LIVIA 2.0
Number of subjects: 234

Group type: COMPARATOR
Intervention: LIVIA 1
Number of subjects: 234
Study: 35737460

Group type: EXPERIMENTAL
Intervention: sNFL measurement with covariate adjustment
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: sNFL measurement
Number of subjects: 571
Study: 35737639

Group type: EXPERIMENTAL
Intervention: CC-90011 (once per week in 28-day cycles)
Number of subjects: 69
Study: 35737873

Group type: EXPERIMENTAL
Intervention: Ixazomib in combination with cyclophosphamide and dexamethasone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ixazomib maintenance after 12 cycles of treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Time to alternate therapy
Number of subjects: 35
Study: 35737961

Group type: EXPERIMENTAL
Intervention: Powered wheelchair
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simulator-based practice
Number of subjects: 30
Study: 35738652

Group type: EXPERIMENTAL
Intervention: CT-QFR
Number of subjects: 216
Study: 35738711

Group type: EXPERIMENTAL
Intervention: Lowest income quartile (Q1)
Number of subjects: 5974

Group type: COMPARATOR
Intervention: Highest income quartile (Q4)
Number of subjects: 5974

Group type: EXPERIMENTAL
Intervention: Income level Q3
Number of subjects: 5974

Group type: EXPERIMENTAL
Intervention: Income level Q4
Number of subjects: 5974
Study: 35738745

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral cerclage ventriculoplasty
Number of subjects: 19
Study: 35738747

Group type: EXPERIMENTAL
Intervention: Self-expandable valves (SEVs)
Number of subjects: 7528
Study: 35738971

Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 1 (previously PPV23-immunized)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 2 (PPV23-naïve)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 1
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 2
Number of subjects: 129

Group type: COMPARATOR
Intervention: Comparison of GMTs between Group 1 and Group 2
Number of subjects: 129

Group type: COMPARATOR
Intervention: Comparison of GMTs between Indigenous and non-Indigenous patients
Number of subjects: 129
Study: 35738999

Group type: EXPERIMENTAL
Intervention: Trametinib 2mg oral daily along with TAS-102 starting at 35 mg/m
Number of subjects: 25
Study: 35739094

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (3 doses)
Number of subjects: 0
Study: 35739300

Group type: EXPERIMENTAL
Intervention: Axitinib (up to 8 weeks pre-surgical)
Number of subjects: 20
Study: 35739539

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (BPD-DS)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Gastric bypass or sleeve gastrectomy (RYGB + SG)
Number of subjects: 2
Study: 35740079

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (LDRT) 0.5 Gy
Number of subjects: 30
Study: 35740322

Group type: EXPERIMENTAL
Intervention: Acute Pulmonary Embolism (PE) diagnosed in patients with venous congestion (VC)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Segments with venous congestion (VC)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Venous diameters in segments with AO
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Arterial diameters in segments with AO
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Alveolar opacities (AO) without venous congestion (VC)
Number of subjects: 268
Study: 35740433

Group type: EXPERIMENTAL
Intervention: BAL eosinophilia (N = 21)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No BAL eosinophilia (N = 36)
Number of subjects: 63

Group type: COMPARATOR
Intervention: BAL neutrophilia (N = 41 participants)
Number of subjects: 63

Group type: COMPARATOR
Intervention: BAL lymphocytosis (N = 27 participants)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Peripheral blood eosinophilia at various thresholds (2%, N = 37; 3%, N = 27; 4%, N = 16)
Number of subjects: 63
Study: 35740603

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) at 3 mg/m²
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fractionated doses of Gemtuzumab ozogamicin (GO3)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CLAG-M (cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone)
Number of subjects: 66
Study: 35740832

Group type: EXPERIMENTAL
Intervention: Early physiotherapy intervention (parental education sessions, tactile and kinesthetic stimulation during NICU, home-based activity program)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care based on NIDCAP-care
Number of subjects: 48
Study: 35741698

Group type: EXPERIMENTAL
Intervention: Motor neuron disease patients (MND)
Number of subjects: 13
Study: 35742400

Group type: EXPERIMENTAL
Intervention: e-OTCAT program during 12 consecutive weeks since the beginning of chemotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Educational handbook and usual care
Number of subjects: 98
Study: 35743333

Group type: EXPERIMENTAL
Intervention: Dr Kawashima's Brain Training
Number of subjects: 0
Study: 35743360

Group type: EXPERIMENTAL
Intervention: Preoperative platelet reactivity to P2Y12 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35743736

Group type: EXPERIMENTAL
Intervention: Dupilumab + Best Supportive Care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 0
Study: 35746653

Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omicron-RBD
Number of subjects: 0
Study: 35747193

Group type: EXPERIMENTAL
Intervention: PT-112 (125 mg/m)
Number of subjects: 66
Study: 35747196

Group type: EXPERIMENTAL
Intervention: Permethrin-treated scarves (PTS) worn for 28 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 58
Study: 35747402

Group type: EXPERIMENTAL
Intervention: Low plasma mannose-binding lectin (p-MBL) levels (≤500 µg/l) in RPL patients
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: High plasma mannose-binding lectin (p-MBL) levels (>3000 µg/l) in RPL patients
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Intermediate plasma mannose-binding lectin (p-MBL) levels (501-3000 µg/l) in RPL patients
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Low p-MBL levels in the first pregnancy after admission
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Maternal p-MBL levels before and after RPL diagnosis
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Overall outcomes of RPL patients during follow-up
Number of subjects: 267
Study: 35747712

Group type: EXPERIMENTAL
Intervention: Sintilimab in combination with concurrent chemoradiotherapy (cCRT)
Number of subjects: 34
Study: 35747751

Group type: EXPERIMENTAL
Intervention: Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35747850

Group type: EXPERIMENTAL
Intervention: Muscle cramps
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Joint and muscle aches
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Muscle weakness
Number of subjects: 334
Study: 35747889

Group type: EXPERIMENTAL
Intervention: 2CARE clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CARE-HD clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CREST-E clinical trial
Number of subjects: 0
Study: 35748318

Group type: EXPERIMENTAL
Intervention: Postprandial studies with whole-body positron emission tomography/computed tomography (PET/CT) using oral [18F]fluoro-thia-heptadecanoic acid and dynamic PET/CT with intravenous [11C]palmitate
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Increased adipose tissue DFA trapping
Number of subjects: 39
Study: 35748699

Group type: EXPERIMENTAL
Intervention: Fazirsiran 200 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohorts 1 and 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fazirsiran 100 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohort 1b)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fazirsiran (all cohorts)
Number of subjects: 16
Study: 35748707

Group type: EXPERIMENTAL
Intervention: IV ganaxolone (low, 500 mg/day; medium, 650 mg/day; high, 713 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IV ganaxolone
Number of subjects: 17
Study: 35748853

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (BNT162b2, mRNA-1273, or ChAdOx1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (BNT162b2, mRNA-1273)
Number of subjects: 0
Study: 35749004

Group type: EXPERIMENTAL
Intervention: Teclistamab (JNJ-64007957)
Number of subjects: 0
Study: 35749016

Group type: EXPERIMENTAL
Intervention: 3D vision system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Binocular microscope
Number of subjects: 60
Study: 35749069

Group type: EXPERIMENTAL
Intervention: Barrett toric formula
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Holladay toric formula
Number of subjects: 3

Group type: COMPARATOR
Intervention: Generic vergence formula with zero surgically induced astigmatism
Number of subjects: 3
Study: 35749216

Group type: EXPERIMENTAL
Intervention: Location-triggered messages
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Reflections on the benefits of change
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Coach monitoring
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Household support
Number of subjects: 62
Study: 35749284

Group type: EXPERIMENTAL
Intervention: C5 siRNA-LNP combined with CsA and DSG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control siRNA-LNP combined with CsA and DSG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C5 siRNA-LNP
Number of subjects: 0
Study: 35749582

Group type: EXPERIMENTAL
Intervention: Rhinovirus (RV) positive samples
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Sequenced RV samples
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Community-based surveillance
Number of subjects: 1066
Study: 35750354

Group type: EXPERIMENTAL
Intervention: SPL-108 with weekly paclitaxel
Number of subjects: 14
Study: 35750419

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 12
Study: 35750422

Group type: EXPERIMENTAL
Intervention: COVID-19 group (cases)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (without COVID-19)
Number of subjects: 150
Study: 35750559

Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) during surveillance cystoscopy
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) following TURBT
Number of subjects: 181

Group type: COMPARATOR
Intervention: Prior exposure to HAL
Number of subjects: 181

Group type: COMPARATOR
Intervention: No prior intravesical therapy
Number of subjects: 181
Study: 35750580

Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography (CAG)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Delayed coronary angiography (CAG)
Number of subjects: 69
Study: 35750602

Group type: EXPERIMENTAL
Intervention: Anode end directed towards the patients' face (experimental group, EC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 48
Study: 35750622

Group type: EXPERIMENTAL
Intervention: Concealed-needle blunt-tip device
Number of subjects: 11
Study: 35750655

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) meditation program (10 minutes)
Number of subjects: 19
Study: 35750695

Group type: EXPERIMENTAL
Intervention: CX-5461 (G-quadruplex stabilizer)
Number of subjects: 40
Study: 35750958

Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) 1-100 g in healthy volunteers
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) 25-100 g in oncology participants
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) 100 g
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) up to 100 g
Number of subjects: 33
Study: 35751082

Group type: EXPERIMENTAL
Intervention: COMID-P (Patient version of the complexity assessment tool)
Number of subjects: 159

Group type: COMPARATOR
Intervention: COMID (Nurse version of the complexity assessment tool)
Number of subjects: 159
Study: 35751122

Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) during clinic visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) at home with PCP encouragement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) at home without PCP encouragement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) in the PC office
Number of subjects: 0
Study: 35751496

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel at 260 mg/m² combined with S-1 (80-120 mg/day, d1-14, q3w) for 6 cycles followed by 8 cycles of S-1 monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel at 180 mg/m²
Number of subjects: 0
Study: 35751715

Group type: EXPERIMENTAL
Intervention: Weight loss intervention using a telehealth platform
Number of subjects: 122
Study: 35751738

Group type: EXPERIMENTAL
Intervention: Miscarriage history
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Anemia in pregnancy
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Preterm premature rupture of membranes (PPROM)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Placenta previa
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Threatened miscarriage
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Premature rupture of membranes (PROM)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Progesterone use
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Abnormal amniotic fluid volume
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Multiple gestations
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Uterine fibroids
Number of subjects: 1033
Study: 35751748

Group type: EXPERIMENTAL
Intervention: COVID(+) athletes underwent additional exercise testing, echocardiography and cardiac magnetic resonance imaging (CMR)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: SARS-Cov-2 testing, ECG and biomarker profiling (D-Dimer, troponin, C-reactive protein)
Number of subjects: 950